Load of challenge Marek's disease virus DNA in blood as a criterion for early diagnosis of Marek's disease tumors.
Outbreaks of Marek's disease (MD) in vaccinated flocks still occur sporadically and lead to economic losses. Unfortunately, adequate methods to predict MD outbreaks are lacking. In the present study, we have evaluated whether high load of challenge MD virus (MDV) DNA in peripheral blood could aid in the early diagnosis of MD and in monitoring efficacy of vaccines against MD. One experiment was conducted to simulate field conditions by combining various vaccines (turkey herpesvirus [HVT] and HVT + MDV serotype 2 [SB1]) and challenge viruses (GA, Md5, and 648A). Vaccine efficacy among our experimental groups ranged from 13.3% to 94.2%. Each chicken was sampled three times during the length of the experiment (3, 5, and 15 wk postchallenge [wpc]), and gross lesions were evaluated in chickens that died and at termination of the experiment. DNA was extracted from whole blood and buffy coats from each sample, and the load of challenge MDV DNA and HVT DNA were quantified by real-time polymerase chain reaction. Chickens that developed MD by the end of the experiment had higher load of challenge MDV DNA (threshold cycle [Ct] glyceraldehyde-3-phosphate dehydrogenase [GAPDH]/Ct glycoprotein B [gB] ratios of 1.0, 1.04, and 1.05 at 3, 5, and 15 wpc, respectively) than those that did not develop MD (Ct GAPDH/Ct gB ratios of 0.7, 0.69, and 0.46 at 3, 5, and 15 wpc, respectively). However, load of HVT DNA in blood was not correlated with the development of tumors (Ct GAPDH/Ct HVT ratios from 0.04 to 0.10 in both groups). Vaccinated groups with >75% protection had statistically significant less challenge DNA virus (Ct GAPDH/Ct gB ratios of 0.76, 0.70, and 0.45 at 3, 5, and 15 wpc, respectively) than less protected groups (Ct GAPDH/Ct gB ratios of 0.92, 0.97, and 0.85 at 3, 5, and 15 wpc, respectively). No differences in the load of HVT DNA could be found between protected and nonprotected groups at any time point of the study (Ct GAPDH/Ct HVT from 0.05 to 0.09 in both groups). Our results showed that load of challenge MDV DNA but not load of HVT DNA in blood can be used as criterion for early diagnosis of MD.
Gimeno
Isabel M
IM
Population Health and Pathobiology Department, College of Veterinary Medicine, North Carolina State University, 4700 Hillsborough Street, Raleigh, NC 27606, USA. isabel_gimeno@ncsu.edu
Cortes
Aneg L
AL
Silva
R F
RF
D000818:Animals; D001483:Base Sequence; D002645:Chickens; D017931:DNA Primers / Q000235:genetics; D004279:DNA, Viral / Q000097:blood* / Q000235:genetics; D004196:Disease Outbreaks / Q000517:prevention & control / Q000662:veterinary; D005260:Female; D026002:Herpesvirus 1, Meleagrid / Q000235:genetics / Q000302:isolation & purification; D008381:Herpesvirus 2, Gallid / Q000235:genetics / Q000302:isolation & purification; D008297:Male; D008380:Marek Disease / Q000175:diagnosis* / Q000453:epidemiology / Q000517:prevention & control / Q000821:virology; D022501:Marek Disease Vaccines / Q000235:genetics / Q000494:pharmacology; D008954:Models, Biological; D019562:Viral Load / Q000662:veterinary
D017931:DNA Primers; D004279:DNA, Viral; D022501:Marek Disease Vaccines